The integration of artificial intelligence (AI) into drug discovery has revolutionized the pharmaceutical industry, offering unprecedented opportunities to accelerate the development of new therapies. However, this technological advancement also poses significant challenges to traditional drug pricing models. This article explores the evolution of drug pricing models in the context of AI-driven drug discovery, examining the implications of AI on cost structures, value-based pricing, and market dynamics. We provide a comprehensive analysis of current pricing strategies, the role of AI in reducing R&D costs, and the potential for new pricing models that align with the value delivered by AI-driven therapies. The article concludes with recommendations for policymakers, pharmaceutical companies, and healthcare providers to navigate the complexities of drug pricing in this new era.